Hyloris Pharmaceuticals SA, known for reinventing exciting medications for unmet medical needs, has announced the approval of Maxigesic® IV, in the UK and Ireland. Maxigesic IV is a unique concoction of of 1000mg paracetamol and 300mg ibuprofen solution for infusion and aims to treat post-operative pain. The approval of Maxigesic IV has brought the number of countries where Hyloris’ partner AFT Pharmaceuticals has gained regulatory approvals to 27. Every year in the UK and Republic of Ireland there are around 3.1 million surgical procedures which are performed, a number which is expected to grow $122.1 million by 2028 at a CAGR of 13.23% from 2017-2028.

Read more here.

More on: